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Abstract 
ROR1 is a member of the ROR receptor family consisting of two closely related type I transmembrane 
proteins, ROR1 and ROR2. Due to mutations in their canonical motifs required for proper kinase 
activity, RORs are classified as pseudokinases lacking detectable catalytic activity. ROR1 stands out for 
its selective and high expression in numerous blood and solid malignancies compared to a minimal 
expression in healthy adult tissues, suggesting high potential for this molecule as drug target for cancer 
therapy. Current understanding attributes a survival role for ROR1 in cancer cells, however its 
oncogenic function is cancer-type specific and involves various signaling pathways. High interest in 
ROR1 targeted therapies resulted in the development of ROR1 monoclonal antibodies such as 
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cirmtuzumab, currently in phase I clinical trial for CLL. Despite these advances in translational studies, 
the molecular mechanism employed by ROR1 in different cancers is not yet fully understood, therefore 
more insights into the oncogenic role of ROR1 signaling are crucial in order to optimize the use of 
targeted drugs. Recent studies provided evidence that targeting ROR1 simultaneously with inhibition 
of BCR signaling is more effective in killing ROR1-positive leukemia cells, suggesting a synergistic 
correlation between co-targeting ROR1 and BCR pathways. Although this synergy has been previously 
reported for B-ALL, the molecular mechanism appears rather different. These results provide more 
insights into ROR1-BCR combinatorial treatment strategies in hematological malignancies, which could 
benefit in tailoring more effective targeted therapies in other ROR1-positive cancers. 
 
ROR family of pseudokinases 
ROR family of proteins belongs to the non-canonical Wnt signaling pathway and comprises of two type 
I, single-pass transmembrane glycoproteins, ROR1 and ROR2, closely related to MuSK (muscle-specific 
kinase) and Trk (tropomyosin) family receptors [1, 2].  
The extracellular region (ectodomain) contains an immunoglobulin-like domain (IgG), a cysteine-rich 
domain (CRD) with sequence and structural similarities to the CRD of Frizzled proteins followed by a 
Kringle domain. A single transmembrane helix connects the ectodomain to the cytoplasmic region, 
which contains a tyrosine kinase-like or pseudokinase domain followed by two serine/threonine 
(Ser/Thr) rich domains flanking a proline (Pro) rich domain (Figure 1A). ROR ligands were initially 
unknown, hence their “orphan” denomination, however subsequent studies have demonstrated that 
both ROR1 and to a greater extent ROR2 are able to bind Wnt5a presumably via their extracellular CRD 
domain [3–7]. ROR Kringle domain, a highly-folded cysteine-rich domain that mediates protein-ligand 
interaction in coagulation proteins, appears to play a role in ROR1/ROR2 heterodimerization and 
subsequent activation of Rho/Rac1 GTPase pathway in leukemia cells [7]. The cytoplasmic tyrosine 
kinase-like domain lacks several conserved residues important for phosphotransferase activity, 
therefore RORs are classified as pseudokinases (Figure 1B). Although early studies reported evidence 
of autocatalytic activity for both ROR1 and ROR2 [1, 8, 9], the prevailing view of RORs is as inactive 
pseudokinases, since using purified recombinant proteins the nucleotide binding and autocatalytic 
activity could not be detected for either of ROR [10, 11].  X-ray crystallographic studies of 
unphosphorylated ROR2 pseudokinase domain revealed an activation loop that occludes the 
substrate- and ATP- binding sites via the unique position of Tyr555 side chain, a feature not observed 
in other kinases [12]. Sequence alignment of ROR1 and ROR2 pseudokinase domains shows high-level 
of homology (Figure 1B), indicative of similar functional mechanisms. Interestingly, restoration of 
glycine-rich loop to its canonical consensus sequence does not result in an increased in vitro catalytic 
activity for purified ROR cytoplasmic domains, suggesting a predominantly non-catalytic function for 
these pseudokinases [10]. Functional evidence for ROR1 catalytic activity came from studies using 
mutation of the invariant Lys506 in 3-sheet to create a kinase dead enzyme.  ROR1 K506A mutant 
could not sustain downstream signaling and growth advantage in lung adenocarcinoma cells 
suggesting that ROR1 kinase activity is required for cell survival [13]. Similar studies have shown that 
ROR1 could trans-phosphorylate HER3 at a previously unidentified Tyr1307 site and this 
phosphorylation was abolished by using ROR1 K506A kinase dead mutant [14]. While K506A mutation 
may alter ROR1 structural integrity and compromise its downstream signaling without affecting its so-
called kinase activity, the possibility of a very low or atypical enzymatic activity could exist. The 
insolubility of both RORs K506R mutants as recombinant proteins (cytoplasmic domain) compared to 
fully soluble wild-type proteins leave us unable to provide a clear biochemical evidence for the effect 
of this mutation on ROR catalytic properties in vitro [10]. Phosphorylation of ROR1 has been observed 
in cell lysates by using either ROR1 phospho-specific or pan-phosphotyrosine antibodies, and several 
kinases including Src and Met were shown to directly interact with and phosphorylate ROR1, 
demonstrating that ROR1 takes part in the dynamic network of intracellular phosphorylation events 
either as a substrate or presumably as an active kinase [13, 15–17]. While ROR1/ROR2 
heterodimerization occurs in response to Wnt5a binding, ligand-induced ROR1/ROR2 trans-
phosphorylation or auto-phosphorylation have not been detected thus far [7, 10]. The ability of ROR1 
to phosphorylate exogenous substrates needs to be investigated beyond K506A mutant 
overexpression, ruling out the possibility that intermolecular interactions could be responsible for the 
observed functional effect. 
The Pro-rich domain of ROR1 serves as substrate for Met phosphorylation in cells with Met-
amplification and as a binding site for Src kinase, while recent reports have added new functions for 
this domain as binding site for 14-3-3ζ and HS1 (hematopoietic cell-specific Lyn substrate 1) to mediate 
downstream signaling leading to cell proliferation and leukemia cell migration [13, 15, 16, 18, 19]. On 
the other hand, ROR2 Pro-rich domain serves as a binding site and substrate for CKI kinase resulting 
in serine-threonine phosphorylation of the second Ser/Thr domain followed by subsequent tyrosine 
phosphorylation of ROR2 pseudokinase domain [3]. The functional role of the C-terminal Ser/Thr 
domains in ROR1 awaits further studies.  
ROR family of proteins are evolutionally conserved and share relatively high level of homology from 
Drosophila to mammals, underlining their important biological functions [20]. In line with this, 
mROR1−/− mice show postnatal growth retardation and have a reduced life expectancy, whereas 
mROR2−/−mice die at birth due to severe skeletal and heart abnormalities [21–23].  mROR1/mROR2-
deficient mouse showed a more severe phenotype than mROR2−/− alone, indicating that mROR1 and 
mROR2 are functionally redundant during embryonic development [24] .  
The strong ROR1 expression during normal embryonic and fetal development is not sustained in all 
postpartum healthy tissues. Low ROR1 levels were detected in adipose cells and to a lesser degree in 
the pancreas, lung and a subset of intermediate B cells [25–27]. Moreover, using a more sensitive 
ROR1-specific monoclonal antibody recent studies have shown relatively high expression levels of 
ROR1 in parathyroid, pancreatic islets and multiple regions in the gut [28]. However, upregulation of 
ROR1 is commonly detected in both hematological and solid tumors [29], which attracted high 
scientific interest to explore the functional advantage of targeting ROR1 expression in cancer cells as a 
therapeutic strategy.   
 
ROR1 and hematological cancers  
ROR1 overexpression was initially identified on B-cells from chronic lymphocytic leukemia (CLL) but not 
on normal B-cells from healthy donors, suggesting that ROR1 expression could become a marker for 
CLL [25]. Furthermore, several research groups have identified ROR1 but not ROR2 expression in many 
other hematological malignancies, indicating that ROR1 is more prevalent in blood cancers. ROR1 
upregulation was detected in primary samples of mantle cell lymphoma (MCL), marginal zone 
lymphoma (MZL), diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), and high levels 
of ROR1 expression is seen in B-ALL patients with the t(1;19)(q23;p13) translocation [27, 30, 31]. It is 
now generally acknowledged that ROR1 expression is commonly detected in NHLs, ranging from high 
levels in CLL to moderate levels in MCL or MZL, suggesting that ROR1 could play a role in the induction 
and/or maintenance of B-cell lymphomagenesis.  
A careful assessment of ROR1 expression on normal and leukemic B cells at different stages of B-cell 
development has helped us to understand how malignant B cells acquired ROR1 for their survival 
advantage. ROR1 expression is completely absent at early stages of normal B-cell development, 
becomes highly expressed at intermediate/late stages (on precursor B cells called hematogones), and 
is then downregulated in normal, mature B cells. On the other hand, ROR1 expression was observed in 
both, intermediate and mature B-cell malignancies suggesting that retention of ROR1 expression 
beyond the intermediate stage could be an important survival step for these mature, malignant B cells 
[26, 27, 32]. Supporting this idea, recent transcriptome analysis of CLL patient samples showed that 
CLL cells with higher ROR1 expression levels have enhanced activation of AKT signaling compared to 
CLL cells with lower ROR1 expression, and this correlated with enhanced disease progression and 
shorter survival rate [33]. Similarly, ROR1 expression in t(1;19) B-ALL cells could sustain pro-survival 
signaling through activation of MEK/ERK and AKT pathways [27]. These pathways control numerous 
cellular responses, such as proliferation, cell cycle entry, survival, metabolic pathway activation, 
apoptosis and angiogenesis. Interestingly, low ROR2 expression was found on both, normal CD5+ B-
cells as well as malignant B cells isolated from CLL patients. ROR1/ROR2 heterodimerization is required 
for Wnt5a-mediated chemotaxis and proliferation of leukemic CLL cells [7]. Apart from ROR1 and 
ROR2, Wnt5a binds to RYK (receptor tyrosine kinase) and PTK7 (protein tyrosine kinase 7), two other 
pseudokinases from the RTK family [34]. Wnt5a plays a variety of roles in different types of tumors, 
and the complexity of its signaling pathways depends largely on the receptors expression, downstream 
effectors, exogenous inhibitors and tumor microenvironments, as well as the existing cross-talk with 
the canonical Wnt-pathways [35]. It remains to be investigated whether the non-canonical Wnt5a-
ROR1/ROR2 pathway is functional in other ROR-positive hematological cancers.  
 
ROR1 targeted therapies  
Given the restricted overexpression of ROR1 on tumor cells and not on most healthy adult tissues, 
several studies have started to explore ROR1 targeted therapies. Two major pharmacological strategies 
were developed: monoclonal antibodies (mAb) targeting the extracellular domain of the receptor, and 
low molecular weight compounds that target the intracellular domain. Silencing ROR1 expression with 
siRNA resulted in efficient apoptosis of leukemic cells, and the same cytotoxic effect was observed by 
targeting ROR1 with mAb [36, 37]. Several ROR1 mAbs have been developed and their cytotoxic 
properties depended largely on their distinctive epitopes. ROR1 mAbs targeting the CRD or Kringle 
domain were more effective in directly killing CLL cells than CD20 mAb rituximab, currently approved 
for advanced CLL treatment, whereas antibodies directed against IgG-like domain were less cytotoxic 
in directly mediating apoptotic effects [37, 38]. Humanized ROR1 mAb cirmtuzumab or UC-961 
targeting an epitope at the junction of IgG-like and CRD domain demonstrated specific and high 
cytotoxic effect against ROR1-positive leukemic cells in vitro and in vivo, and currently advanced to 
phase I clinical trial for CLL [39]. The preclinical efficacy of UC-961 in other ROR1-positive cancers 
including solid tumors such as ovarian cancer indicated that this mAb could have broader therapeutic 
application. More studies will be required to fully characterize the direct or indirect effector 
mechanisms of different ROR1 mAbs and their potential interference with yet unknown 
receptor/ligand interactions leading to undesired agonistic activity. On the other hand, targeting the 
intracellular domain of ROR1 by small molecule inhibitor such as KAN0439834 demonstrated promising 
preclinical efficiency by inducing high levels of apoptosis/necrosis in CLL cells, indicating that ROR1 
could become a druggable therapeutic target [40].  
A better understanding of the signaling pathway downstream ROR1 has been derived from recent 
studies using mass-spectrometry analysis of ROR1 immunoprecipitated samples from CLL cells. Wnt5a 
binding can induce ROR1/ROR2 dimerization and enhance cell proliferation and/or leukemia-cell 
migration. ROR1 mAb UC-961 was shown to compete with Wnt5a and abrogate the heterodimerization 
of ROR1/ROR2 and subsequent intracellular signaling cascade employing guanine exchange factors 
(GEFs) and their downstream effectors Rho and Rac1 resulting in inhibition of cell proliferation and 
chemokine-induced migration [7]. Though most of the attention has been focused on ROR1 signaling 
in CLL models, a deeper understanding of ROR1 molecular pathways in other hematological cancers 
will help in designing more effective targeted therapies.  
 
Co-targeting BCR and ROR1 in B-cell malignancies 
Mature B lymphocytes are essential antibody-producing cells of the immune system harboring B-cell 
receptors that recognize foreign antigens. Signals via the BCRs are responsible for 
development/maturation, proliferation, maintenance, and activation of normal B lymphocytes and 
proceed through several downstream BCR-related kinases [41]. These signaling events are not only 
prevalent but also overexpressed in malignant B lymphocytes, and targeting various components of 
this pathway appear to be the most promising therapy. As such, inhibition of BCR-downstream effector 
kinases demonstrated high therapeutic efficacy as evidenced by past and ongoing clinical trials for BTK 
inhibitor ibrutinib, Syk inhibitor fostamatinib, and PI3K inhibitor idelalisib [42–45]. Considerable 
attention has been given to ibrutinib for its unprecedented clinical efficacy as a single agent in CLL and 
MCL patients [46]. However, tumor relapse is still a challenging fate for many patients, indicating that 
combinatorial treatment strategies must be considered.  
Although ROR1 and BCR signaling pathways are driven by the engagement of unrelated cell-surface 
receptors, a regulatory feedback loop via common downstream mediators has been identified in B-ALL 
cells [27]. Silencing of pre-BCR expression in t(1;19) B-ALL cells resulted in significant up-regulation of 
ROR1 protein levels, suggesting an intrinsic regulatory mechanism that function via PI3K/AKT pathway 
to maintain cell growth and viability. Pre-BCR silencing induced a positive feedback loop for 
upregulation of ROR1 expression, which in turn drives reactivation of AKT signaling resulting in 
increased cell-survival. As such, simultaneous ROR1 knockdown and pre-BCR inhibition is more 
effective in killing t(1;19)B-ALL cells than targeting either pathway alone, as demonstrated by the 
effectiveness of dasatinib treatment (a multi-kinase inhibitor targeting BTK and Src kinases 
downstream BCR pathway) together with siRNA-mediated ROR1 silencing (Figure 2).  
A similar synergism has been recently described for leukemic CLL cells, where co-targeting ROR1 and 
BTK by cirmtuzumab and ibrutinib co-treatment is more effective in killing leukemia cells in vitro and 
in vivo than either agent alone [47] (Figure 2). Wnt5a-induced Rac1 activation could be inhibited by 
cirmtuzumab treatment but not by ibrutinib-mediated BTK-inhibition, suggesting that ROR1 and BCR 
signaling pathways are independently modulated in CLL cells. The synergistic effect of cirmtuzumab 
and ibrutinib could provide a solution for already challenging ibrutinib acquired resistance, as it occurs 
in many patients undergoing ibrutinib monotherapy.  
Combination therapy is now widely considered as the optimal strategy especially for overcoming drug-
resistance more permanently. Therefore, a significant amount of research is currently focused on 
identifying and testing rational combinatorial treatments. Co-targeting BCR and non-canonical Wnt 
signaling pathways in blood cancers is an area less investigated thus far. The functional link between 
ROR1 and pre-BCR signaling converging downstream at the level of AKT/PI3K phosphorylation in B-ALL 
cells indicates that common signaling mediators can significantly modulate the outcome of 
combinatorial therapies. While is unknown whether ROR1 signaling in B-ALL requires ligand-mediated 
activation, in CLL cells Wnt5a binding can increase motility and chemotactic responses of ROR1 
expressing cells. Inhibition of ROR1 signaling by cirmtuzumab resulted in decreased cell proliferation 
and chemokine-directed migration, indicating that Wnt5a-ROR1 signaling is involved in leukemia cell 
chemotaxis, a function not related to ROR1 kinase activity [7].  Several BCR effector kinases such as 
BTK, PI3K and Syk play important roles in pathways activated by tumor-microenvironment interactions, 
therefore BCR targeted inhibitors are known to interfere with chemokine-mediated migration of CLL 
cells, impending the ability of cancer cells to "home" to the microenvironment [45, 48, 49]. As such, 
we could hypothesize that co-targeting ROR1 and BCR signaling will trigger this common effector 
mechanism and will result in augmented inhibition of chemokine-mediated migration of leukemic cells 
and their survival signals from tumor microenvironment. Targeting ROR1 offers the advantage of low 
cytotoxicity due to its restricted expression in healthy adult tissue, therefore the additional toxicity 
that may be expected with combination therapy could be significantly minimized. Interestingly, 
another Wnt5a binding and catalytically inactive pseudokinase PTK7 was found to be expressed in AML 
(acute myeloid leukemia) and its expression correlated with increased leukemic cell migration, survival 
and resistance to anthracycline-induced apoptosis [11, 50]. This could indicate that chemotaxis is a 
common mechanism mediated by non-canonical Wnt receptor pseudokinases in leukemic cells.  
The complexity of BCR signaling regulation in various NHLs is directly reflected by different sensitivities 
of BCR targeted drugs for each disease model. Therefore, some drug combinations could synergize 
better in a particular disease type but not in others. Consequently, a combination therapy by co-
targeting ROR1 and BCR signaling should be carefully investigated for each ROR1-positive lymphoma 
entities in order to identify more specific and effective combinatorial treatments.  
 
Conclusion 
Past and ongoing clinical trials with targeted drugs in cancer have shown us that single drugs are rarely 
effective in achieving long-term remission due to existing or acquired compensatory pathways. From 
this perspective, effective cancer treatments will only come from the rational combination of targeted 
agents, derived from a deep knowledge of signaling pathways and their interconnectedness. While 
currently is difficult to predict the true clinical potential of ROR1 targeted therapy (either by mAbs or 
small molecule inhibitors), results obtained thus far could provide a glimpse of the future. Therefore, 
it seems safe predicting that anti-ROR1 agents, especially mAbs, will likely be combined with other 
targeted drugs in order to achieve the best clinical outcome. Taken together, from the perspective of 
therapeutic efficacy, these preclinical observations support the concept that a combination therapy 
with ROR1 and BCR targeted agents for ROR1-positive B-cell malignancies will likely be clinically 
advantageous. 
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Figure 1. ROR pseudokinases structure and sequence alignment.  
A. Schematic diagram of ROR1. The extracellular region comprises of an immunoglobulin (IgG)-like domain, a 
cysteine-rich domain (CRD) or Frizzled domain and a Kringle domain. The cytoplasmic domain contains the 
pseudokinase domain followed by two serine-threonine rich domains flanking a proline-rich domain. The CRD is 
important for binding of Wnt ligands. Kringle domain is required for ROR2 heterodimerization in response to 
Wnt5a ligand binding, whereas the intracellular proline-rich domain binds cytoplasmic adaptor proteins.  
B. Sequence alignment of the human ROR1 and ROR2 pseudokinase domains (amino acids 473-746) by 
ClustalW-MUSCLE method. Residues mutated in ROR pseudokinase domains are depicted in red color. 
Consensus sequences of typical kinase domain are depicted in green color and positioned above the 
corresponding residues in RORs.  
 
Figure 2: Co-targeting ROR1 and BCR pathways in B-ALL and CLL.  
Diagram of model for how inhibition of ROR1 signaling works in synergy with inhibition of BCR signaling in B-ALL 
or CLL models. Targeting ROR1 with cirmtuzumab (magenta color) and BTK with ibrutinib (grey color) in CLL cells 
results in synergistic inhibition of cell proliferation, survival and cell-migration. In B-ALL cells, inhibition of BTK 
by dasatinib (navy-blue color) results in upregulation of ROR1 expression, whereas inhibition of both, ROR1 
(green color) and BTK leads to simultaneous inhibition of cancer cell biological functions.  
 
  
 
